A PHASE III, MULTICENTRE, INTERNATIONAL STUDY WITH A PARALLEL, RANDOMISED, DOUBLE BLIND, PLACEBO CONTROLLED, 2 ARM DESIGN TO ASSESS THE EFFICACY AND SAFETY OF SELUMETINIB IN ADULT PARTICIPANTS WITH NF1 WHO HAVE SYMPTOMATIC, INOPERABLE PLEXIFORM NEUROFIBROMAS (KOMET)

Registry ID

D134BC00001

Source registry

HEALTH_CANADA

Status

Ongoing

Phase

PHASE3

Study type

INTERVENTIONAL

Sponsor

ASTRAZENECA AB

Start date

2024-02-20

Last update

2021-06-18

Conditions

• NEUROFIBROMATOSIS TYPE I

Related clinical trials

• PHASE II STUDY OF IMATINIB MESYLATE (PMS) IN NEUROFIBROMATOSIS TYPE I PATIENTS AGED 2 TO 21 WITH PLEXIFORM NEUROFIBROMAS

View on source registry